Ernexa Therapeutics Inc. (ERNA)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Sanjeev Luther | CEO, President & Director | 625k | -- | 1962 |
| Ms. Sandra M. Gurrola | Principal Financial & Accounting Officer and Senior VP of Finance | 275k | -- | 1967 |
| Ms. Dorothy J. Clarke | General Counsel | -- | -- | 1966 |
| Dr. Robert Hamilton Pierce M.D. | Chief Scientific Officer | -- | -- | 1964 |
Ernexa Therapeutics Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 6
Description
Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of solid tumors and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-102, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc. and changed its name to Ernexa Therapeutics in March 2025. Ernexa Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Corporate Governance
Upcoming Events
August 11, 2025 at 8:00 PM UTC - August 15, 2025 at 8:00 PM UTC
Ernexa Therapeutics Inc. Earnings Date
Recent Events
April 25, 2025 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission